These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 22397669)

  • 41. miR-204-5p inhibits proliferation and invasion and enhances chemotherapeutic sensitivity of colorectal cancer cells by downregulating RAB22A.
    Yin Y; Zhang B; Wang W; Fei B; Quan C; Zhang J; Song M; Bian Z; Wang Q; Ni S; Hu Y; Mao Y; Zhou L; Wang Y; Yu J; Du X; Hua D; Huang Z
    Clin Cancer Res; 2014 Dec; 20(23):6187-99. PubMed ID: 25294901
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Activator protein 2alpha status determines the chemosensitivity of cancer cells: implications in cancer chemotherapy.
    Wajapeyee N; Raut CG; Somasundaram K
    Cancer Res; 2005 Oct; 65(19):8628-34. PubMed ID: 16204029
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MicroRNA-587 antagonizes 5-FU-induced apoptosis and confers drug resistance by regulating PPP2R1B expression in colorectal cancer.
    Zhang Y; Talmon G; Wang J
    Cell Death Dis; 2015 Aug; 6(8):e1845. PubMed ID: 26247730
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Silencing GOLPH3 gene expression reverses resistance to cisplatin in HT29 colon cancer cells via multiple signaling pathways.
    Zhou ZP; Wang LP; Hong ZS; Qiu CZ; Wang MZ; Chen ZX; Tang LF; Yu WS; Wang CX
    Int J Oncol; 2018 Sep; 53(3):1183-1192. PubMed ID: 30015866
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Decellularized matrices as in vitro models of extracellular matrix in tumor tissues at different malignant levels: Mechanism of 5-fluorouracil resistance in colorectal tumor cells.
    Hoshiba T; Tanaka M
    Biochim Biophys Acta; 2016 Nov; 1863(11):2749-2757. PubMed ID: 27558478
    [TBL] [Abstract][Full Text] [Related]  

  • 46. DNA stool test for colorectal cancer: hypermethylation of the secreted frizzled-related protein-1 gene.
    Zhang W; Bauer M; Croner RS; Pelz JO; Lodygin D; Hermeking H; Stürzl M; Hohenberger W; Matzel KE
    Dis Colon Rectum; 2007 Oct; 50(10):1618-26; discussion 1626-7. PubMed ID: 17762966
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel methylation panel for the early detection of neoplasia in high-risk ulcerative colitis and Crohn's colitis patients.
    Azuara D; Rodriguez-Moranta F; de Oca J; Sanjuan X; Guardiola J; Lobaton T; Wang A; Boadas J; Piqueras M; Monfort D; Galter S; Esteller M; Moreno V; Capellá G
    Inflamm Bowel Dis; 2013 Jan; 19(1):165-73. PubMed ID: 22532293
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer.
    To KK; Leung WW; Ng SS
    Exp Cell Res; 2015 Nov; 338(2):222-31. PubMed ID: 26386386
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Drug resistance, predictive markers and pharmacogenomics in colorectal cancer.
    Longley DB; Allen WL; Johnston PG
    Biochim Biophys Acta; 2006 Dec; 1766(2):184-96. PubMed ID: 16973289
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gambogic acid inhibits growth, induces apoptosis, and overcomes drug resistance in human colorectal cancer cells.
    Wen C; Huang L; Chen J; Lin M; Li W; Lu B; Rutnam ZJ; Iwamoto A; Wang Z; Yang X; Liu H
    Int J Oncol; 2015 Nov; 47(5):1663-71. PubMed ID: 26397804
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Elevated expression of TrpC5 and GLUT1 is associated with chemoresistance in colorectal cancer.
    Wang T; Ning K; Lu TX; Hua D
    Oncol Rep; 2017 Feb; 37(2):1059-1065. PubMed ID: 28000878
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intratumor heterogeneity: finding the needle in a haystack for cancer treatment.
    Camps J; Ried T; Castells A
    Gastroenterology; 2013 Jul; 145(1):242-244. PubMed ID: 23726878
    [No Abstract]   [Full Text] [Related]  

  • 53. Methylation of SLFN11 is a marker of poor prognosis and cisplatin resistance in colorectal cancer.
    He T; Zhang M; Zheng R; Zheng S; Linghu E; Herman JG; Guo M
    Epigenomics; 2017 Jun; 9(6):849-862. PubMed ID: 28403629
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Overcoming stemness and chemoresistance in colorectal cancer through miR-195-5p-modulated inhibition of notch signaling.
    Jin Y; Wang M; Hu H; Huang Q; Chen Y; Wang G
    Int J Biol Macromol; 2018 Oct; 117():445-453. PubMed ID: 29852230
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular markers of chemotherapy in advanced colorectal cancer: back to square one.
    Sobrero A
    Eur J Cancer; 2009 Jul; 45(11):1902-3. PubMed ID: 19502051
    [No Abstract]   [Full Text] [Related]  

  • 56. Expression of Cancer Testis Antigens in Colorectal Cancer: New Prognostic and Therapeutic Implications.
    Tarnowski M; Czerewaty M; Deskur A; Safranow K; Marlicz W; Urasińska E; Ratajczak MZ; Starzyńska T
    Dis Markers; 2016; 2016():1987505. PubMed ID: 27635108
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical utility of gene microarray for the management of colorectal cancer.
    D'Orazio A
    Clin Colorectal Cancer; 2006 May; 6(1):25-8. PubMed ID: 16796787
    [No Abstract]   [Full Text] [Related]  

  • 58. A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer.
    Arcaroli JJ; Tai WM; McWilliams R; Bagby S; Blatchford PJ; Varella-Garcia M; Purkey A; Quackenbush KS; Song EK; Pitts TM; Gao D; Lieu C; McManus M; Tan AC; Zheng X; Zhang Q; Ozeck M; Olson P; Jiang ZQ; Kopetz S; Jimeno A; Keysar S; Eckhardt G; Messersmith WA
    Int J Cancer; 2016 Jan; 138(1):195-205. PubMed ID: 26152787
    [TBL] [Abstract][Full Text] [Related]  

  • 59. TET1 Depletion Induces Aberrant CpG Methylation in Colorectal Cancer Cells.
    Kai M; Niinuma T; Kitajima H; Yamamoto E; Harada T; Aoki H; Maruyama R; Toyota M; Sasaki Y; Sugai T; Tokino T; Nakase H; Suzuki H
    PLoS One; 2016; 11(12):e0168281. PubMed ID: 27977763
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HRAS G13D, a new mutation implicated in the resistance to anti-EGFR therapies in colorectal cancer, a case report.
    Boidot R; Chevrier S; Julie V; Ladoire S; Ghiringhelli F
    Int J Colorectal Dis; 2016 Jun; 31(6):1245-6. PubMed ID: 26561417
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.